WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent in Japan for its aPKCi inhibitor platform, a potential breakthrough in treating hedgehog pathway-dependent cancers. The patent, numbered 7603605, will remain in effect until 2040.
The aPKCi inhibitor platform targets a group of cancers linked to the hedgehog signaling pathway, including basal cell carcinoma, medulloblastoma, small cell lung cancer, rhabdomyosarcoma, and other malignancies. The patented technology includes both topical and oral formulations, developed in collaboration with Cancer Research UK and leading academic institutions. Additionally, the platform supports combination therapies using hedgehog pathway inhibitors alongside HDAC inhibitors to amplify anti-cancer effects.
“This new patent for our oncology preclinical aPKCi inhibitor strengthens our pipeline and is a vital step in our development strategy,” said Jed Latkin, CEO of Windtree Therapeutics. He emphasized the company’s commitment to expanding its intellectual property portfolio across global markets.
The aPKCi inhibitors are designed as highly potent, specific drug candidates aimed at rare and aggressive cancers. Windtree Therapeutics has also filed a separate patent application addressing crystalline forms of these inhibitors, further advancing its efforts to innovate cancer treatments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.